VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
For more details, the full press release can be accessed at https://ibn.fm/1je4A. VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The announcement is important because it signals VERAXA's progress in developing cancer therapies that may offer greater precision and reduced side effects compared to conventional treatments. The BiTAC platforms could potentially address unmet needs in solid tumor indications, and the company's active pursuit of partnerships at a major industry convention indicates readiness for collaborative development and commercialization.
The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. This content was distributed by BioMedWire, a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio under IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution, and a full array of tailored corporate communications solutions.
